CD34 and Friedreich ataxia: Thus, ensuring a delicate balance between efficiency of gene editing and controlling the DNA damage-repair mechanism, while maintaining the stem cell potency of CD34+ HSPC, is necessary to ensure a safe and efficacious ex vivo gene editing method for FRDA and other diseases.